Erigeron breviscapus is a traditional Chinese medicinal herb that has gained considerable scientific attention for its potential in supporting the eyes, particularly in the context of vascular eye diseases. The primary bioactive component, scutellarin, has been the subject of multiple pharmacological studies. Research, including animal models and clinical trials, has demonstrated that extracts of Erigeron breviscapus can improve microcirculation, inhibit platelet aggregation, and exert antioxidative effects, all of which are relevant to eye health. These properties are particularly beneficial in conditions such as diabetic retinopathy and retinal vein occlusion, where compromised microvascular function plays a central role.

A number of clinical studies published in Chinese medical journals report that intravenous or oral administration of Erigeron breviscapus extract improves visual acuity and reduces retinal damage in patients with diabetic retinopathy. A systematic review (Zhang et al., 2013, J Ethnopharmacol) summarized the efficacy of this herb in microvascular complications, including those of the eye. While most clinical research originates from China and may not always adhere to the strictest international standards, the accumulated evidence is substantial and consistent. The herb's use is also supported by its long history in traditional Chinese medicine for "invigorating blood circulation," a concept closely linked to eye health in that context.

In summary, Erigeron breviscapus has both a traditional basis and growing scientific support for use in promoting eye health, particularly for microvascular eye diseases. However, more large-scale, high-quality trials are needed for unequivocal validation.